Patient adherence with a smartphone app for patient-reported outcomes in rheumatoid arthritis. (23rd June 2020)

• Record Type: Journal Article
• Authors: Colls, Josh; Lee, Yvonne C; Xu, Chang; Corrigan, Cassandra; Lu, Fengxin; Marquez-Grap, Georgia; Murray, Meredith; Suh, Dong H; Solomon, Daniel H
• Is Part Of: Rheumatology. Volume 60:Number 1(2021)
• Page Start: 108
• Page End: 112
• Publication Date: 2020-06-23
• Subjects: rheumatoid arthritis -- digital health -- patient adherence -- patient-reported outcomes -- smartphone app; Rheumatism -- Periodicals; Rheumatology -- Periodicals; 616.723005
• DOI: 10.1093/rheumatology/keaa202
• Languages: English
• ISSNs: 1462-0324

Abstract

Abstract: Objectives: Electronic patient-reported outcomes (ePROs) transmitted digitally allow patients to communicate with their clinicians and track the activity of chronic diseases, such as RA. Several ePRO smartphone apps have been developed in rheumatology, yet few data have been reported regarding patient adherence. We developed a PRO app for RA and assessed adherence over 6 months. Methods: We developed an app to deliver daily assessments to participants (RA App v.1.0). The app was tested as part of a randomized controlled trial examining potential clinical benefits. The current analyses focus on the adherence to the ePRO app for patients randomized to receive the app. We recruited RA patients from an academic rheumatology practice in the USA. Patients randomized to receive the app received daily notifications regarding ePROs. We examined adherence to the PRO questionnaires over the 6-month study and examined factors related to adherence. Results: Seventy-eight patients received the app and have data included in these analyses: 63 (80.7%) were female, mean age was 55.2 years, 71% had attended college or beyond, and the mean Clinical Disease Activity Index at baseline was 9.7 (low disease activity). Median adherence to the daily questions was 79% (interquartile range 48–90%). Significant predictors of increased adherence were age ≥65 ( P = 0.03) and low baseline Clinical Disease Activity Index ( P = 0.02). Conclusion: We developed and tested an ePRO app for RA over a 6-month study. Adherence to the app was strong. There was correlation between older age and better disease control and increased adherence. Trial registration: ClinicalTrials.gov, https://clinicaltrials.gov/, NCT02822521.